Open Orphan (ORPH), a specialist contract research organisation said it noted market speculation regarding a potential delisting. The company confirmed that it has no plans to delist and is working
Traders Cafe with Zak Mir: Bulletin Board Heroes, Monday 25th April 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Boston, Drumz, Empire, Genedrive, Keras, Live,
Traders Cafe with Zak Mir: Bulletin Board Heroes, Thursday 21st April 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Deltex, Empire, Galileo, Induction, Kefi, Live,
Traders Cafe with Zak Mir: Bulletin Board Heroes, Tuesday 19th April 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Arrow Exploration Corp, Alkemy, Argos, Arc,
Traders Cafe with Zak Mir: Bulletin Board Heroes, Wednesday 6th April 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Avacta, Agronomics, COPL, Cobra, Empire, FireAngel,
4d Pharma PLC (AIM:DDDD) Final Results
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
Traders Cafe with Zak Mir: Bulletin Board Heroes, Friday 25th March 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London market. Today’s selection includes Arrow Exploration, Aura, Bidstack, Cyan, Diurnal, Eco, Galantas, Goldstone,
4d Pharma PLC (AIM:DDDD) MRx0518 + Keytruda – Primary endpoint met in RCC
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
4d Pharma PLC (AIM: DDDD) Participation in Chardan Microbiome Summit
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
4d Pharma PLC (AIM: DDDD) Parkinson’s trial receives FDA IND clearance
4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease
4d Pharma PLC (AIM: DDDD) Restatement of Interim Results to June 30, 2021
4D pharma to Restate Unaudited Interim Financial Statements for the Six-Month Period Ended June 30, 2021 to Correct Accounting for Warrants
